<DOC>
	<DOCNO>NCT02507167</DOCNO>
	<brief_summary>The purpose study evaluate impact genetic variant OATP 1B3 MRP 2 systemic disposition endogenously form CCK-8 determine influence single-dose transporter inhibitor rifampin ( 600 mg ) systemic disposition endogenously form CCK-8 . Endogenous CCK-8 secretion induce single-dose standardized liquid mixed meal .</brief_summary>
	<brief_title>Impact Two Genetic Variants OATP1B3 MRP2 Rifampin Systemic Disposition Biological Efficacy CCK-8</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>age : 1845 year sex : male 12 subject homozygote wildtype carrier OATP 1B3 ( c.SLCO 1B3 699 AA c.SLCO 1B3 334 GG ) MRP 2 12 subject homozygotes MRP 2 variant ( genetic loss function ) homozygote wildtype carrier OATP 1B3 12 subject homozygotes OATP 1B3 variant ( c.SLCO 1B3 699 GG c.SLCO 1B3 334 TT ) homozygotes wildtype carrier MRP 2 BMI : ≥ 19 kg/m2 ≤ 27 kg/m2 good health evidence result clinical examination , ECG , laboratory checkup , judge clinical investigator differ clinical relevant way healthy state write informed consent give volunteer provide detailed information ( , verbally write ) nature , risk , scope clinical trial well expect desirable adverse effect drug hepatic renal disease and/or pathological finding , might interfere pharmacokinetics pharmacodynamics study medication gastrointestinal disease and/or pathological finding ( e.g . stenosis ) , might interfere pharmacokinetics pharmacodynamics study medication subject exist dysfunction regulation glucose metabolism , e.g . deficiency glucose6phosphate dehydrogenase ( Glc6P DHG ) and/ pathological finding subject alcohol and/ drug dependence alcohol consumption 20 g alcohol/ day excessive smoking ( 10 cigarette equivalents/ day ) subject positive find HBsAG , HIV and/ drug subject diet ( inclusive special uniform nutritional habit , e.g . vegetarian undercaloric diet ) strong coffee and/ tea consumption ( ≥ 1 liter day ) subject suspected know follow instruction subject unable understand write verbal instruction , particular regard risk inconvenience expose result participation study subject liable orthostatic dysregulation , fainting , blackout subject take part clinical trial last 3 month ( block time due another clinical trial investigational product ) acute illness le 14 past blood donation within last 3 month medication within 4 week prior intend first administration study medication might influence function gastrointestinal tract ( e.g . laxative , metoclopramide , loperamide , antacid , H2receptor antagonists , proton pump inhibitor , anticholinergic ) medication within 2 week prior first administration study medication le 10time halflive respective drug intake grapefruit contain food beverage poppy seed contain product 14 prior first drug administration last blood sampling study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>